Anti-human CD3 (Clone: SP34-2) | Recombinant, in vivo grade

Catalog No.	Product Name	Size	List Price (US$)
PA007196	In vivo Grade Recombinant Anti-human CD3e Monoclonal Antibody (Clone: SP34-2), Mouse IgG1 Lambda	1 mg	150.00
PA007196	In vivo Grade Recombinant Anti-human CD3e Monoclonal Antibody (Clone: SP34-2), Mouse IgG1 Lambda	5 mg	350.00
PA007196	In vivo Grade Recombinant Anti-human CD3e Monoclonal Antibody (Clone: SP34-2), Mouse IgG1 Lambda	25 mg	900.00

Catalog No.

Product Name

Size

List Price (US$)

Quantity

PA007196

In vivo Grade Recombinant Anti-human CD3e Monoclonal Antibody (Clone: SP34-2), Mouse IgG1 Lambda

1 mg

150.00

PA007196

In vivo Grade Recombinant Anti-human CD3e Monoclonal Antibody (Clone: SP34-2), Mouse IgG1 Lambda

5 mg

350.00

PA007196

In vivo Grade Recombinant Anti-human CD3e Monoclonal Antibody (Clone: SP34-2), Mouse IgG1 Lambda

25 mg

900.00

Description

Background of Anti-human CD3 Antibody (Clone: SP34-2)

The anti-human CD3 antibody (clone: SP34-2), a derivative of SP34, is known to cross-react with a major subset of peripheral blood lymphocytes in both human and non-human primates, including baboon, rhesus, cynomolgus, and pigtail macaque monkeys. The SP34-2 antibody specifically recognizes a major subset of CD3-positive cells from non-human primates, similar to its human counterpart, but does not react with monocytes or granulocytes.

The SP34-2 antibody is used in flow cytometry to identify and analyze CD3-positive cells in human and various non-human primate species. It can also be used to stimulate cell proliferation in various primate peripheral blood mononuclear cells (PBMC).

PA007196: In vivo Grade Recombinant Anti-human CD3e Mouse IgG1 Lambda Monoclonal Antibody (Clone: SP34-2)

Recombinant mouse IgG1 Monoclonal Antibody.
Clone: SP34-2.
Isotype: Mouse IgG1 lambda.
Source: The anti-human CD3 monoclonal antibody (clone: SP34-2) was produced in mammalian cells.
Specificity/Sensitivity: The in vivo grade recombinant mouse monoclonal antibody (clone: SP34-2) specifically binds to the human T cell receptor CD3.
Applications: ELISA, neutralization, functional assays such as bioanalytical PK and ADA assays, and those assays for studying biological pathways affected by the human CD3 protein.
Form of Antibody: 0.2 uM filtered solution, pH 7.4, no stabilizers or preservatives.
Endotoxin: < 1 EU per 1 mg of the protein by the LAL method.
Purity: >95% by SDS-PAGE under reducing conditions and HPLC.

Shipping: The antibody is shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage: Use a manual defrost freezer and avoid repeated freeze-thaw cycles.
12 months from date of receipt, -20 to -70°C as supplied.
1 month from date of receipt, 2 to 8°C as supplied.

References of Anti-human CD3e Monoclonal Antibody (Clone: SP34-2)

Bi-specific autoantigen-T cell engagers as targeted immunotherapy for autoreactive B cell depletion in autoimmune diseases

Meng X, et al. Nat Commun. 2024 Mar 9;15(1):2158. doi: 10.1038/s41467-024-46320-y. PMID: 38461145; PMCID: PMC10926275

Autoreactive B cells play a central pathogenic role in many autoimmune diseases, highlighting the need for targeted depletion strategies. This study developed bi-specific autoantigen-T cell engagers designed to selectively redirect T cells to eliminate specific autoantibody-producing B cells without causing broad immunosuppression. Utilizing anti-CD3 antibodies, the engineered engagers successfully activated T cells to specifically eradicate target B cells in preclinical models of autoimmune disease.

(Tags: SP34-2; T cell engager)

A bispecific T cell engager recruits both type 1 NKT and Vγ9Vδ2-T cells for the treatment of CD1d-expressing hematological malignancies

Zhang Y, et al. Nat Commun. 2023 Mar 27;14(1):1664. doi: 10.1038/s41467-023-37397-y. PMID: 36973273; PMCID: PMC10040383

Bispecific T cell engagers (BiTEs) have shown significant clinical efficacy, yet standard approaches often fail to fully exploit the unique properties of unconventional T cell populations. Researchers engineered a novel bispecific engager targeting CD1d and CD3, capable of simultaneously recruiting and activating both type 1 natural killer T (NKT) cells and Vγ9Vδ2-T cells against hematological malignancies. The incorporation of CD3 activation domains effectively triggered these specialized immune cells to exert potent cytotoxicity against CD1d-expressing tumor cells in vivo.

(Tags: Anti-human CD3; Bispecific antibody)

CD3-immunotoxin mediated depletion of T cells in lymphoid tissues of rhesus macaques

Bergamaschi C, et al. JCI Insight. 2023 Oct 9;8(19):e170884. doi: 10.1172/jci.insight.170884. PMID: 37676694; PMCID: PMC10558572

Achieving profound T cell depletion within lymphoid tissues remains a major challenge in solid organ transplantation and the treatment of severe autoimmune conditions. This investigation evaluated a novel recombinant CD3-immunotoxin designed to selectively ablate T lymphocytes directly within the lymph nodes and spleen of non-human primate models. Administration of this CD3-targeted therapy resulted in the rapid and sustained depletion of resident T cells across various lymphoid compartments, demonstrating its potential for robust immunomodulation.

(Tags: Clone SP34-2; Non-human primate)

Cytomegalovirus mediates expansion of IL-15–responsive innate-memory cells with SIV killing function

Vargas-Inchausti C, et al. Front Immunol. 2021 Jul 21;12:695503. doi: 10.3389/fimmu.2021.695503. PMID: 34367156; PMCID: PMC8321572

Cytomegalovirus (CMV) vectors have emerged as highly effective vaccine candidates capable of inducing unconventional, broadly protective immune responses against simian immunodeficiency virus (SIV). This study demonstrates that CMV infection drives the robust expansion of a unique population of IL-15-responsive innate-memory cells exhibiting potent SIV-killing capabilities. T cell functional assays and phenotypic characterizations, facilitated by cross-reactive CD3 antibodies, confirmed the enhanced antiviral effector functions of these specialized cellular subsets.

(Tags: SP34-2; Flow cytometry)

A Novel SIV Gag-Specific CD4+ T-Cell Clone Suppresses SIVmac239 Replication in CD4+ T Cells Revealing the Interplay between Antiviral Effector Cells and Their Infected Targets

Mason RD, et al. J Virol. 2016 Jun 10;90(13):5999-6014. doi: 10.1128/JVI.00551-16. PMID: 27099307; PMCID: PMC4860118

While CD8+ T cells are traditionally recognized for their antiviral cytotoxicity, the direct effector functions of CD4+ T cells in controlling retroviral replication are increasingly appreciated. Researchers isolated and characterized a novel SIV Gag-specific CD4+ T cell clone capable of profoundly suppressing the replication of SIVmac239 within infected target cells. Utilizing comprehensive cellular profiling, including T cell receptor activation via anti-CD3 monoclonal antibodies, the study elucidates the complex mechanistic interplay between antiviral CD4+ effector cells and their viral targets.

(Tags: Anti-human CD3e; T cell activation)